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The following article is reprinted with permission from Elsevier Inc. It was originally published
in the Int. J. Radiation Oncology Biol. Physics, Volume 70, No. 2, pp. 385-390, 2008.
Purpose
Patients with non–small-cell lung cancer (NSCLC) in the Radiation Therapy Oncology Group
(RTOG) 93-11 trial received radiation doses of 70.9, 77.4, 83.8, or 90.3 Gy. The locoregional control
and survival rates were similar among the various dose levels.We investigated the effect of the gross
tumor volume (GTV) on the outcome.
Methods and Materials
The GTV was defined as the sum of the volumes of the primary tumor and involved lymph nodes.
The tumor response, median survival time (MST), and progression-free survival (PFS) were analyzed
separately for smaller (≤45 cm3) vs. larger (>45 cm3) tumors.
Results
The distribution of the GTV was as follows: ≤45 cm3 in 79 (49%) and >45 cm3 in 82 (51%) of 161
patients. The median GTV was 47.3 cm3. N0 status and female gender were associated with better
tumor responses. Patients with smaller (≤45 cm3) tumors achieved a longer MST and better PFS
than did patients with larger (>45 cm3) tumors (29.7 vs. 13.3 months, p < 0.0001; and 15.8 vs. 8.3
months, p < 0.0001, respectively). Increasing the radiation dose had no effect on the MST or PFS.
On multivariate analysis, only a smaller GTV was a significant prognostic factor for improved MST
and PFS (hazard ratio [HR], 2.12, p = 0.0002; and HR, 2.0, p = 0.0002, respectively). The GTV as a
continuous variable was also significantly associated with the MST and PFS (HR, 1.59, p < 0.0001;
and HR, 1.39, p < 0.0001, respectively).
Conclusions
Radiation dose escalation up to 90.3 Gy did not result in improved MST or PFS. The tumor responses
were greater in node-negative patients and women. An increasing GTV was strongly associated
with decreased MST and PFS. Future radiotherapy trials patients might need to use stratification by
tumor volume. ©2008 Elsevier Inc.
Key Words: Tumor volume, Lung cancer, Radiotherapy dose escalation.

Introduction
The current American Joint Committee on Cancer staging system for the primary tumor in lung
cancer is based mostly on the tumor extent and involvement of the neighboring structures (e.g.,
pleura, chest wall, mediastinum, bone, esophagus, and proximal airways) rather than on tumor
size or volume. A notable exception is Stage T1, in which a tumor surrounded completely by lung
parenchyma cannot exceed 3 cm in the largest dimension. However, a Stage T2 tumor can measure
1.5 cm or 8 cm, as long as it invades the visceral pleura only, with sparing of the other structures.

Evidence has been accumulating1–11 that an
increasing tumor volume has a significant
effect on patient outcome, possibly even
overriding the T stage assignment. Other factors
influencing the American Joint Committee on
Cancer stage assignment are nodal involvement
and the presence of distant metastases.
In a recently published Radiation Therapy
Oncology Group (RTOG) Phase I-II study12
of radiation dose escalation for patients
with inoperable non–small cell-lung cancer
(NSCLC), the observed locoregional control
rates and survival rates were similar between
treatment groups, receiving escalated radiation
doses (from 70.9 Gy to 90.3 Gy, depending on
the volume of lung receiving ≥20 Gy [V20]).
A reasonable initial hypothesis would be,
however, to expect that smaller tumors should
demonstrate improved local control with greater
radiation doses compared with larger tumors.
To investigate this hypothesis, we undertook a
retrospective analysis of data from the RTOG
93-11 clinical trial in an attempt to demonstrate
any benefit of radiation dose escalation for
patients with smaller tumors and to determine
any relationship between the initial tumor
volume and patient outcome.

Methods And Materials
Patient population
The RTOG 93-11 study was a Phase I-II
radiation dose escalation trial for patients with
inoperable Stage I-III NSCLC treated with
three-dimensional (3D) radiotherapy alone,
without concurrent chemotherapy, although
induction chemotherapy was allowed.
The primary objective of the study was to
determine the treatment-related morbidity and
to determine the maximal tolerated radiation
dose. The secondary objectives were to
determine the local control and overall survival
(OS) rates. The patient population consisted of
subjects with NSCLC (inoperable Stage I, II,
and IIIA and Stage IIIB; supraclavicular nodes
involvement was not allowed; Table 1). Patients
were treated according to the volumetric
treatment planning computed tomography
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findings and the gross tumor volume (GTV) included the primary
tumor and any enlarged regional lymph nodes (>1 cm) with a minimal
3D margin of 1 cm. Noninvolved nodal areas were not irradiated, and
no special effort was made to account for the respiratory motion, apart
for assessing motion with fluoroscopy. Patients were placed into doseescalation groups according to the V20 value in their radiotherapy (RT)
plan, predicting the likelihood of treatment-related pneumonitis13.
Patients with a V20 of <25% were assigned to Group 1 and received
an escalated dose to 70.9, 77.4, 83.8, or 90.3 Gy. Patients with a V20 of
26–35% were assigned to Group 2 and received an escalated dose to 70.9,
77.4, or 83.8 Gy. Patients with a V20 of >35% were assigned to Group 3
and received an escalating dose to 64.5, 70.9, or 77.4 Gy. All fraction sizes
were 2.15 Gy. The study accrued patients only to Groups 1 and 2. Group
3 enrollment was stopped because of poor accrual.

the purpose of this investigation, tumor response, OS, and PFS were
analyzed separately for the smaller tumors (≤45 cm3) vs. larger tumors
(>45 cm3), first among all patients and, later, within each radiation dose
level. GTV was also analyzed as a continuous variable. The association
of response (CR/PR vs. stable/progressive disease) and the GTV
categorized by cutpoint was tested by Fisher’s exact test. OS and PFS were
estimated by the Kaplan-Meier method and tested using the log–rank
test statistic. Univariate and multivariate analyses of OS and PFS with the
GTV and other prognostic factors (age [<60 vs. ≥60], gender, Karnofsky
performance status [90–100 vs. 70–80], histologic type [nonsquamous
vs. squamous], stage [I-II vs. IIIA-IIIB], previous chemotherapy [yes vs.
no], and maximal radiation dose to the lung) were done using the Cox
proportional hazards model. Multivariate modeling used the stepwise
selection method. When analyzed as a continuous variable, GTV was
transformed using a log10 transformation to ensure normality. Patients
with unknown tumor volumes were excluded from this analysis.

Table 1. Patient characteristics
Characteristic

Group 1 (n = 127)

Group 2 (n = 48)

Age (y)
<60
≥60

18 (14)
109 (86)

5 (10)
43 (90)

Gender (n)
Male
Female

72 (57)
55 (43)

22 (46)
26 (54)

KPS (n)
70–80
90–100

85 (67)
42 (28)

30 (63)
18 (37)

Histologic type (n)
Squamous cell carcinoma
Adenocarcinoma
Other

51 (40)
42 (33)
34 (21)

21 (44)
17 (35)
10 (21)

N stage (n)
N0
N1
N2
N3

83 (65)
10 (8)
32 (25)
2 (1)

17 (35)
6 (13)
22 (46)
3 (6)

Abbreviation: KPS = Karnofsky performance status.
Data in parentheses are percentages.

Evaluation of local control, OS, and progression-free survival
A chest X-ray was obtained 4 weeks after RT completion. Computed
tomography scans of the chest were obtained at 6 and 12 months and
repeated yearly thereafter. Local control (complete response [CR] or
partial response [PR] vs. stable or progressive disease) was reported by
the enrolling institutions. No central review of the follow-up computed
tomography scans was performed. OS and progression-free survival
(PFS) were reported as measured from the date of registration in
the study.
Statistical analysis
The GTV was defined as the sum of the volumes of the primary tumor
and involved lymph nodes. In the 3D plans, the primary tumor volume
and the involved nodal volume were outlined as one structure; no data
are available in the RTOG electronic database to allow for separation of
those two volumes. Therefore, in an attempt to at least partially correct
this deficiency, nodal status (N0 vs. N1 or N2 or N3) was analyzed as
one of the variables. This allowed for the separation of the effect of
the tumor GTV vs. nodal GTV (at least for Stage I, or N0, patients).
OS was defined as death from any cause; an event for PFS was local or
regional progression, distant metastases, or death from any cause. For

30
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Results
Patient characteristics
A total of 176 patients were included in the original report of the study12.
Of the 176 patients, 161 had available data on GTV and tumor response
and were the subject of this secondary analysis. The patient characteristics
are presented in Table 1. Overall, most patients were older (>60 years)
with a Karnofsky performance status between 70 and 80. The patients in
this analysis were approximately equally split between men and women
and those in Group 1 were more likely to have node-negative disease
than were those in Group 2. The distribution of the American Joint
Committee on Cancer stage was Stage I in 67, Stage II in 12, and Stage
III in 48 patients in Group 1 and Stage I in 10, Stage II in 3, and Stage III
in 35 patients in Group 2.
Tumor response, OS, and PFS
The GTV was ≤45 cm3 in 79 (49%) and >45 cm3, 82 (51%) of 161 patients
(median, 47.3; range, 1.9–1,039.9 cm3); 14 patients had an unknown
GTV. The tumor response rate (CR/PR) was better for smaller tumors
(≤45 cm3) than for larger tumors (>45 cm3; 87% vs. 76%, respectively),
as was stable/progressive disease (13% vs. 24%, respectively; p =
0.0691, Fisher’s exact test). Results using a cutoff point of 30 cm3 did
not better distinguish between those patients with a tumor response
and those with stable or progressive disease than using a cutoff point
of 45 cm3 (p = 0.0642). A cutoff point of 60 cm3 did not discriminate
between the two groups (p = 0.4139). When the GTV was analyzed as a
continuous variable, on univariate analysis, it was borderline statistically
significantly associated with tumor response (p = 0.0551); however, on
multivariate analysis, N stage (N0 vs. N1-N3) and female gender were
the only significant variables (p = 0.025 and p = 0.02, respectively). This
can be explained by the greater rate of responses (70%) in patients with
N0 disease vs. N1-N3 (30%).
Patients with smaller tumors (≤45 cm3) achieved a longer median survival
than did patients with larger tumors (>45 cm3; 29.7 vs. 13.3 months, p
< 0.0001; Fig. 1), as well as better median PFS (15.8 vs. 8.3 months; p <
0.0001; Fig. 2).
When a different GTV was chosen as a cutoff point (30 cm3 or 60 cm3),
patients with smaller tumors (≤30 cm3 or ≤60 cm3) still achieved better
OS (32.9 vs. 14.6 months for 30 cm3, p = 0.0002; and 26.8 vs. 13.3 months
for 60 cm3, p = 0.0006), as well as better PFS (15.5 vs. 9.0 months for 30
cm3, p = 0.0031; and 14.7 vs. 8.7 months for 60 cm3, p = 0.0023).

Studies

On multivariate analysis of the factors associated with improved OS
and PFS, only a smaller tumor volume was significantly prognostic
for both endpoints (HR, 2.12; p = 0.0002; and HR, 2.0; p = 0.0002,
respectively) when GTV was analyzed as a continuous variable. Age,
gender, performance status, histologic type, N stage (N0 vs. N1-N3),
previous chemotherapy, and maximal radiation dose were not significant
(Tables 2 and 3). The other GTV cutoff points (≤30 cm3, ≤45 cm3, and ≤60
cm3) retained their statistically significant association with improved OS
and PFS on multivariate analysis and again were the only factors in the
multivariate models using a stepwise selection method.
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Figure 2. Five-year progression-free survival rate for patients with gross
tumor volume ≤45 cm3 (solid curve) vs. those with gross tumor volume
>45 cm3 (dotted curve).
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Table 2. Multivariate analysis of overall survival for
different gross tumor volumes used as cutoff point and
as continuous variable
Model*

Comparison

Hazard ratio

95% CI

p†

3

GTV (cm )

<30 vs. ≥30

2.18

1.43–3.32

0.0003

GTV (cm3)

≤45 vs. >45

2.12

1.43–3.13

0.0002

3

12

/

0

0
0

Median

≤ 45 cc 56/79
> 45 cc 74/82

/

29.7 months
13.3 months

// / /
// /

25

/

Median

/
///

Fail/Total

100

0

p<0.0001 (log-rank test)

/

(data not shown). The consistently statistically significant increase in the
relative risk of death for all doses to a GTV >45 cm3 can be attributed to
the strong effect of a larger GTV on OS rather than the radiation dose.
However, the analysis was not powered to detect a dose–tumor volume
interaction, and it could not be ruled out on the basis of this analysis.

% Alive Without Progression

When the effect of GTV was analyzed on univariate analysis, a smaller
GTV was associated with improved OS, with significant hazard ratios
(HRs) for cutoff points of 30 cm3 (HR, 2.15; p = 0.0002); 45 cm3 (HR,
2.14; p < 0.0001); and 60 cm3 (HR, 1.91; p = 0.0008), as well as for GTV
analyzed as a continuous variable (HR, 1.59; p < 0.0001). The other
variables associated with improved OS on univariate analysis were female
gender (p = 0.0407) and nodal status (p = 0.067, borderline significance).
The same factors were significant for PFS on univariate analysis (data
not shown).

24

36

48

Months Since Randomization
Figure 1. Five-year overall survival rate for patients with gross tumor
volume ≤45 cm3 (solid curve) vs. those with gross tumor volume >45
cm3 (dotted curve).
Effect of radiation dose escalation on tumor response, OS, and PFS by
tumor volume
The primary research hypothesis of this study was that higher radiation
doses would lead to increased efficacy in smaller tumors. Table 4 shows
the frequencies and percentages of patients with a CR/PR and stable or
progressive disease for each radiation dose and GTV combination using
the 45 cm3 cutoff point. No evidence was found in these data that the CR/
PR rates increased as the radiation dose increases for the two categories
of GTV (p = 0.2213). Increasing the radiation dose had no effect on OS
or PFS (data not shown for PFS) when examined separately for smaller
vs. larger tumors when the 45-cm3 GTV cutoff point was used (Table
5). The results for the 30-cm3 and 60-cm3 cutoff points were similar

GTV (cm )

≤60 vs. >60

1.87

1.27–2.75

0.0015

GTV‡

Continuous

1.59

1.33–1.91

<0.0001

Abbreviation: CI = confidence interval; GTV = gross tumor volume; KPS = Karnofsky performance status.
*Following covariates did not meet entry criteria for any multivariate model: age (<60 vs. ≥60 y), gender
(female vs. male), KPS (90–100 vs. 70–80), histologic type (nonsquamous vs. squamous), N stage (N0 vs.
N1-N3), previous chemotherapy (no vs. yes), or maximal dose to lung (continuous).
†
Chi-square test using Cox proportional hazards model; stepwise selection, with entry level of 0.05 and exit
level of 0.10.
‡
GTV transformed using log10 to ensure normalcy.

Discussion
The aim of RTOG 93-11 was to determine the dose-limiting toxicity of
3D RT. The radiation dose was safely escalated to 83.8 Gy for patients
with V20 <25% and to 77.4 Gy for patients with a V20 of 25–36%. The
90.3-Gy dose level was too toxic. The observed locoregional control was
similar among the study arms, without evidence that the higher doses
eliminated or at least lowered the recurrence rates.
Our initial hypothesis was that patients with volumetrically smaller
tumors would have improved survival with radiation dose escalation but
not patients with larger tumors. However, we were not able to demonstrate
that in this secondary analysis of the RTOG 93-11 trial, at least not with
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Table 3. Multivariate analysis of progression-free survival for
different gross tumor volumes used as cutoff point and as
continuous variable

Hazard ratio

Comparison

Hazard ratio

95% CI

p†

3

GTV ≤45 cm , dose 83.8 Gy

17

1.60

0.65–3.93

0.3058

GTV (cm3)

<30 vs. ≥30

1.74

1.20–2.53

0.0039

GTV ≤45 cm3, dose 77.4 Gy

17

1.10

0.43–2.82

0.8432

GTV (cm3)

≤45 vs. >45

2.00

1.40–2.86

0.0002

GTV ≤45 cm3, dose 70.9 Gy

14

1.57

0.63–3.91

0.3301

GTV (cm3)

≤60 vs. >60

1.65

1.16–2.36

0.0056

GTV >45 cm3, dose 90.3 Gy

9

4.20

1.52–11.64

0.0058

GTV‡

Continuous

1.39

1.18–1.64

<0.0001

3

GTV >45 cm , dose 83.8 Gy

13

3.83

1.53–9.60

0.0041

Abbreviations as in Table 2.
*Following covariates did not meet entry criteria for any multivariate model: age (<60 vs. ≥60 y), gender
(female vs. male), KPS (90–100 vs. 70–80), histologic type (nonsquamous vs. squamous), N stage (N0 vs.
N1-N3), previous chemotherapy (no vs. yes), or maximal dose to lung (continuous).
†
Chi-square test using Cox proportional hazards model; stepwise selection, with entry level of 0.05 and exit
level of 0.10.
‡
GTV was transformed using log10 to ensure normality.

GTV >45 cm3, dose 77.4 Gy

28

2.41

1.06–5.48

0.0361

GTV >45 cm3, dose 70.9 Gy

30

2.61

1.17–5.84

0.0193

the small patient numbers that were available at each radiation dose
level tested. It could be that doses >83.8 Gy in standard fractions are
necessary to eliminate local failure. Additionally, the protracted overall
treatment time of 7–9 weeks might have facilitated tumor repopulation
and therefore attenuated any radiation dose response. Finally, the
PTV margins were tight (1–1.5 cm around the GTV), which might
have increased the likelihood for a marginal miss in mobile tumors,
obliterating any potential benefit of dose escalation.

In the reports of highly hypofractionated (‘‘radioablative’’) RT using
precise localization techniques to account for tumor motion, very high
local control rates have been achieved in medically inoperable patients
with Stage I NSCLC receiving 60 Gy in three fractions of 20 Gy each10
or other hypofractionated regimens11. Such doses have not yet been
tested in Stage III NSCLC and might be too dangerous for large and
central tumors.

A significant interaction between radiation dose and tumor size was
shown in the University of Michigan retrospective analysis5 of 114
patients with medically inoperable Stage I and II NSCLC treated with 3D
conformal RT in a dose-escalation study. Patients treated to a biologically
equivalent dose of ≤79.2 Gy lived longer if their tumors did not exceed
51.8 cm3 in volume. However, patients treated to a biologically equivalent
dose of >79.2 Gy had the same overall survival, irrespective of tumor
volume. With all the limitations of the retrospective study, a hypothesis
has been raised that radiation dose escalation can result in improved
outcome in NSCLC, at least in node-negative, early-stage tumors.

Table 4. Frequency of tumor response subdivided by radiation
dose level and gross tumor volume cutpoint of 45 cm3
Incidence (n)
3

GTV ≤45 cm

CR/PR

SD/PD

p*

Dose 70.9 Gy
Dose 77.4 Gy
Dose 83.8 Gy
Dose 90.3 Gy
Dose 70.9 Gy
Dose 77.4 Gy
Dose 83.8 Gy
Dose 90.3 Gy

13 (93)
14 (82)
15 (88)
23 (88)
21 (70)
19 (68)
12 (92)
8 (89)

1 (7)
3 (18)
2 (12)
3 (12)
9 (3)
9 (32)
1 (8)
1 (11)

0.2736

Abbreviation: CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease;
GTV = gross tumor volume.
Data in parentheses are percentages.
*Fisher’s exact test.
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Model*

95% CI

p†

n

Model*

Such a benefit has been suggested in the Memorial Sloan-Kettering
Cancer Center experience4, with the observation of improved local
control and survival in Stage III NSCLC patients with large (>100 cm3)
tumors treated with radiation doses >64 Gy compared with those who
received lower radiation doses.

32

Table 5. Multivariate analysis of overall survival subdivided by
radiation dose level and gross tumor volume cutpoint of 45 cm3

Abbreviations as in Table 4.
Reference level: GTV ≤45 cm3, dose 90.3 Gy.
*Chi-square test using Cox proportional hazards model.

We found that the increasing tumor volume, defined as the sum of the
primary tumor volume and the volume of the involved lymph nodes,
was associated with a greater risk of local failure, with significantly better
control achieved with tumors <45 cm3 than with the larger tumors. The
45-cm3 volume corresponds roughly to a spherical tumor diameter of
4.4 cm. It must be remembered that the ‘‘tumor volume’’ in our analysis
denoted a sum of the volume of the primary tumor and the involved
lymph nodes, if any. However, in the multivariate analysis of the tumor
volume studied as a continuous variable, it was only the earlier nodal
stage and female gender, not the tumor volume, that was associated with
better local control. In reality, those two variables (volume and nodal
stage) overlap to a large degree, because Stage I NSCLC is defined as a
node-negative tumor measuring ≤3 cm in the largest dimension. Separate
values for the primary GTV and the nodal GTV were not available in the
RTOG 93-11 study; therefore, we were unable to isolate their respective
influences on outcomes.
Because a rigorous evaluation of locoregional control was not performed
in the RTOG 93-11 trial, local control was not assessed in an actuarial
fashion and the radiographic responses might not reflect the true biologic
tumor elimination; using survival as an endpoint is a more objective
measure of the relevance of tumor volume. A strong association of
increasing tumor volume with worsened survival and PFS was observed
in our analysis, overriding other known prognostic factors for survival,
such as lower disease stage.
Such an association has been previously reported1–9. In 207 patients with
inoperable NSCLC (Stage I-III) treated at the Washington University
with 3D-conformal thoracic RT1, overall survival, cause-specific
survival, and local tumor control were highly correlated with the GTV,
and the GTV (and pathologic findings) were predictive for survival on
multivariate analysis, but overall stage and nodal stage were not. Those
patients with tumor volumes not exceeding 33 cm3 appeared to have the
best outcome.
Local response was evaluated volumetrically on 107 followup thoracic
computed tomography scans of 22 patients (19 with Stage III NSCLC)
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10. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: Results of a phase
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Investigators from Shanghai Medical University8 created a prognostic
index model predicting for local control in patients with NSCLC treated
with RT. Patients with a smaller tumor volume (primary plus nodal),
earlier clinical stage, and treated with higher total irradiation dose with
a shortened overall treatment time had better local control.
In a Classification and Regression Tree analysis of the Thomas Jefferson
University’s 107 patients with Stage III NSCLC (9), an aggregate nodal
volume >12.5 cm3 (sum of volumes of the abnormal hilar and mediastinal
lymph nodes), as well as a central tumor location, but not the primary
tumor volume, were associated with a greater risk of nodal recurrence
and shorter median survival time than a nodal volume of ≤12.5 cm3
(MST 13.9 months vs. 17.1 months, respectively). We are not aware of
other reports that have focused on the prognostic value of the involved
nodal volume.

Conclusions
Our study is one of several publications demonstrating the importance
of tumor volume in patients receiving thoracic RT for NSCLC. It is not
fully clear whether patients with smaller tumors have better outcomes
simply because of the lower number of clonogenic cells or whether
smaller tumors are inherently more biologically favorable; however, the
tumor volume may need to be considered in the staging system for lung
cancer, once user-friendly volume assessment becomes commonplace in
diagnostic studies.
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